|Articles|November 14, 2022

Top 6 Trends for Hospitals and Health Systems in 2023

In 2023, hospitals and healthcare systems will rapidly modernize to navigate a fast-expanding competitive landscape. In this guide, review the trends that will drive decision-makers in healthcare systems.

In 2023, hospitals and healthcare systems will rapidly modernize to navigate a fast-expanding competitive landscape. Private Equity (PE) investments are fueling consolidation, reimbursement regulations are shifting and more procedures are moving from hospitals to outpatient settings. What’s the plan to build operational resilience and revenue growth for hospitals and health systems in 2023?

In this guide, review the trends that will drive decision-makers in healthcare systems, including:

Rapid upgrades to patient-engagement technology, due to insights from the pandemic
The reimbursement challenge, as a result of new regulations and policy changes
How digital-first patient experiences are differentiating health systems in the patient’s eyes

Complete the form below to learn more.

Top 6 Trends for Hospitals and Health Systems in 2023

Newsletter

Related Content

Innovating care for vulnerable populations white paper

Unlock Cost Savings Through Digital Payment Outsourcing

Clinical and Economic Impact of OAB Symptoms in Men Receiving Pharmacological Treatment for BPH

Why Savings Don’t Materialize: The Truth about PBM Procurement

AI-driven brain health platform for payers

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Missouri

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Kentucky

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

20th Annual New York Lung Cancers Symposium®

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

2nd Annual Hawaii Cancer Conference

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

27th Annual International Lung Cancer Congress®

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

23rd Annual Winter Lung Cancer Conference®

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

21st Annual New York Lung Cancers Symposium®

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Trending on Managed Healthcare Executive

What IRA drug prices will mean for PBMs, health plans and patients

Biosimilar competition could surpass IRA-negotiated savings by year three

Catheter ablation shows benefits for patients with both aFib and sleep apnea

Ultra-processed foods linked to early-onset colorectal adenomas in women

Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026